Do we have more T cell immunity to SARS-CoV-2 than we think?


Grifoni et al., 2020 Graphical Abstract

Grifoni et al., 2020 Graphical Abstract

A recently published article in Cell showed the presence of SARS-CoV-2−reactive CD4+ T cells in up to 60% of unexposed individuals – suggesting the presence of cross-reactive T cells. The authors used a set of peptide ‘megapools’, derived from predicted peptides restricted by several HLA class I and II, and found that 70-100% of COVID-19 convalescent patients had reactive SARS-CoV-2−specific CD8+ and CD4+ T cells. CD4+T cell responses to spike appeared immunodominant and “correlated with the magnitude of the anti-SARS-CoV-2 IgG and IgA titers.” There appeared to be a hierarchy of CD4+ T cells responses to the M, spike and N proteins, as well as responses to nsp3, nsp4, ORF3a and ORF8. CD8+ T cells also recognized the spike and M proteins, with “at least eight SARS-CoV-2 ORFs targeted.” These results show that SARS-CoV-2 infected individuals make robust T cell responses to the virus, which is important information towards vaccine development. However, the finding that SARS-CoV-2 unexposed individuals could also react with these peptide pools suggests a level of pre-existing immunity that may have been derived from infection with the circulating ‘common cold’ coronaviruses. Does this translate to some form of protection?

 Journal Article: Grifoni et al., 2020. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 

Article by Clive Gray

 
 
 
 
 
 
International Union of Immunological SocietiesUniversity of South AfricaInstitute of Infectious Disease and Molecular MedicineScience Education PrizesElizabeth Glazer Pediatric Aids FoundationAlere
 

Accessibility Toolbar